David's Shield Integrates Amish Self-Sufficiency Methods with Faraday Cage Construction and Non-Electric Survival Techniques ...

SAN FRANCISCO and SUZHOU, China, June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...

Veronica Paulus is a former STAT intern supported by the Harvard University Institute of Politics. GLP-1 drugs could treat more than just diabetes and obesity. They may also reduce migraine frequency.

Eric K. Singhi, M.D., is an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, and Ben Creelan, M.D., is ...

-- Company to host a live webcast event with an expert panel of clinicians during EHA2025 -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling participants. The historically tight-lipped Amgen execs remain judicious with ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...

As I open Your Word today, please speak to the depths of my heart and open my mind to the truth found within these beautiful pages. I long to gain wisdom and live in a manner that pleases You.

A Metro Detroit teen is participating in a five-year double-blind controlled trial using a 125-year-old tuberculosis vaccine. Dr. Denise Faustman, originally from Michigan, is using the drug BCG in ...

An important handbook used by enlisted airmen to study for their promotion evaluations has been removed by the Air Force following President Donald Trump's executive orders eliminating all diversity ...

The initial changes, which featured in a USCIS policy manual update on August 27, stated that F-1 visa holders studying abroad for longer than five months could no longer remain actively enrolled in a ...

Background: Zilebesiran is an investigational subcutaneous (SC) RNA interference therapeutic targeting hepatic angiotensinogen synthesis. In the Phase 2 KARDIA-1 study (NCT04936035), changes in blood ...